Amgen2021: Advanced Solid Tumors with KRAS p.G12C Mutation - Clinical Trial

What is the Purpose of this Study?

We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.

What is the Condition Being Studied?

Colorectal Adenocarcinoma with KRAS p.G12C Mutation

Who Can Participate in the Study?

Adults ages 18+ who:

- Are diagnosed with advanced or metastatic colorectal adenocarcinoma with KRAS p.G12C mutation

- Have not received any previous therapy for metastatic disease

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Grupo etario

Adultos

What is Involved?

Si elige unirse a este estudio, podrá:

- Get a random assignment (like a coin flip) to 1 of 2 groups

-- One group will get the study drug combination of sotorasib, panitumumab, and FOLFIRI

-- The other group will get FOLFIRI either on its own or with another drug called bevacizumab-awwb

- Hacerse una biopsia del tumor, si es necesario

- Realizar extracciones de sangre

- Hacerse estudios de imágenes (tomografía computarizada o resonancia magnética)

Study Details

Full Title

Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

Principal Investigator